Regulation of CDK9 activity by phosphorylation and dephosphorylation

Sergei Nekhai1, Michael Petukhov2, Denitra Breuer1

  • 1Center for Sickle Cell Disease, Department of Medicine, Howard University, 520 W Street, N.W. Washington, DC 20059, USA.

Insights

This study reviews kinases and phosphatases regulating HIV-1 transcription via CDK9 phosphorylation. It proposes a novel pathway involving CDK2 and protein phosphatase-1 for potential drug development targeting HIV-1 replication.

Area of Science:

  • Molecular biology
  • Virology
  • Biochemistry

Background:

  • HIV-1 transcription relies on CDK9/cyclin T1 kinase.
  • This kinase associates with the 7SK snRNP complex, a process not fully understood.
  • CDK9 phosphorylation reversibly regulates this association.

Purpose of the Study:

  • To review kinases and phosphatases involved in CDK9 phosphorylation.
  • To discuss their role in HIV-1 replication regulation.
  • To explore potential drug targets for HIV-1 treatment.

Main Methods:

  • Comprehensive literature review of kinases and phosphatases.
  • Analysis of CDK9 phosphorylation sites and regulatory mechanisms.
  • Discussion of proposed novel regulatory pathways.

Main Results:

  • Identified key kinases and phosphatases influencing CDK9 activity.
  • Highlighted the importance of reversible CDK9 phosphorylation in HIV-1 transcription.
  • Proposed a novel pathway: CDK2 phosphorylates CDK9 at Ser-90, and PP1 dephosphorylates CDK9 at Ser-175.

Conclusions:

  • CDK9 phosphorylation is a critical regulatory point in HIV-1 transcription.
  • The identified kinases (CDK2) and phosphatases (PP1) offer potential therapeutic targets.
  • Understanding these mechanisms can lead to new anti-HIV drug development strategies.

Related Concept Videos

Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
4.8K
Inhibition of CDK Activity02:34

Inhibition of CDK Activity

4.3K